Sign In
Buy ONCY
$0.94
+0.0237 (+2.58%)
At Close: Jun 23, 2026
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
08:30am, Tuesday, 05'th Aug 2025
The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO and CALGARY, AB , Aug. 5, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq
Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities S
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
09:39am, Wednesday, 23'rd Jul 2025
SAN DIEGO and CALGARY, AB , July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a k
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
03:32pm, Tuesday, 22'nd Jul 2025
SAN DIEGO and CALGARY, AB , July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immuno
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
08:30am, Wednesday, 16'th Jul 2025
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
08:30am, Thursday, 10'th Jul 2025
KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET SAN DIEGO and CALGARY, AB , July 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage com
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent surviv
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
07:00am, Monday, 30'th Jun 2025
SAN DIEGO and CALGARY, Alberta , June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
07:00am, Wednesday, 11'th Jun 2025
SAN DIEGO and CALGARY, AB , June 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today annou
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
07:00am, Friday, 23'rd May 2025
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-inf
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
07:21pm, Wednesday, 14'th May 2025
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chair
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
04:01pm, Wednesday, 14'th May 2025
American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic imm
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
07:00am, Tuesday, 06'th May 2025
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-s
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
07:00am, Thursday, 24'th Apr 2025
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest an
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
06:09pm, Thursday, 10'th Apr 2025
SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entere
